**Core Concept**
Phenytoin is an antiepileptic medication that belongs to the hydantoin class. It is primarily metabolized by the liver enzyme CYP2C9 and has several pharmacokinetic properties that are essential to understand in clinical practice.

**Why the Correct Answer is Right**
Phenytoin exhibits zero-order kinetics at therapeutic doses, meaning that its metabolism rate is independent of its plasma concentration. This is due to the saturation of the enzyme CYP2C9, which is responsible for its metabolism. As a result, small increases in plasma concentration can lead to disproportionately large increases in the area under the curve (AUC) and subsequently, the risk of toxicity. In contrast, phenytoin is indeed teratogenic, especially during the first trimester of pregnancy, and is highly protein-bound, which affects its distribution and elimination. However, phenytoin does not stimulate insulin secretion; instead, it can cause hypoglycemia due to its inhibitory effect on glucose release from the liver.

**Why Each Wrong Option is Incorrect**
**Option A:** Phenytoin follows zero-order kinetics at therapeutic doses, not saturation kinetics, which is a characteristic of drugs that exhibit first-order kinetics until saturation occurs.
**Option B:** Phenytoin is indeed teratogenic, and its use during pregnancy is associated with an increased risk of congenital malformations.
**Option C:** Phenytoin is highly protein-bound, with approximately 90% of its plasma concentration bound to albumin, which affects its distribution and elimination.

**Clinical Pearl / High-Yield Fact**
Phenytoin's unique pharmacokinetic properties can lead to a narrow therapeutic index, making it essential to monitor plasma concentrations to avoid toxicity. A level of 10-20 mg/L is typically considered therapeutic, while levels above 30 mg/L can be associated with toxicity.

**✓ Correct Answer:** D. Stimulates Insulin secretion